Clinical Trials
12 trialsNCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT05911308 2025-03-21
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT02710396 2023-07-24
Genetic Predictors of Benefit to Pembrolizumab
Columbia University
Phase 2 Terminated
NCT02382406 2023-05-23
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT03138889 2023-03-10
PROPEL
Nektar Therapeutics
Phase 1/2 Terminated
NCT02967133 2022-09-08
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Terminated
NCT04060342 2022-08-18
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Phase 1 Terminated
NCT00470548 2018-01-10
Abraxane and Alimta in Advanced Solid Tumors
University of California, Davis
Phase 1/2 Terminated
NCT02276560 2017-05-11
LCCC1407
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT02319889 2017-02-01
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT00544648 2014-06-09
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
Vanderbilt-Ingram Cancer Center
Phase 1/2 Terminated